| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| Schizoaffective Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Psychotic Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 4 | Interventions listed in this trial | ||||
| Aripiprazole | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antipsychotic Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 6 | Sponsors listed in this trial | ||||
| Bristol-Myers Squibb | |||||
| Otsuka America Pharmaceutical | |||||
|
